Reduced somatostatin signalling leads to hypersecretion of glucagon in mice fed a high-fat diet

Objectives:&nbsp;Elevated plasma glucagon is an early symptom of diabetes, occurring in subjects with impaired glucose regulation. Here, we explored alpha-cell function in female mice fed a high-fat diet (HFD)&mdash;a widely used mouse model of prediabetes. Methods:&nbsp;We fed female mice expressing the Ca2+&nbsp;indicator GCaMP3 specifically in alpha-cells an HFD or control (CTL) diet. We then conducted&nbsp;in&nbsp;vivo&nbsp;phenotyping of these mice, as well as experiments on isolated (ex&nbsp;vivo) islets and in the&nbsp;in situ&nbsp;perfused pancreas. Results:&nbsp;In&nbsp;vivo,&nbsp;HFD-fed mice exhibited increased fed plasma glucagon levels and a reduced response to elevations in plasma glucose. Glucagon secretion from isolated islets and in the perfused mouse pancreas was elevated under both hypo- and hyperglycaemic conditions. In mice fed a CTL diet, increasing glucose reduced intracellular Ca2+&nbsp;([Ca2+]i) (oscillation frequency and amplitude). This effect was also observed in HFD mice; however, both the frequency and amplitude of the [Ca2+]i&nbsp;oscillations were higher than those in CTL alpha-cells. Given that alpha-cells are under strong paracrine control from neighbouring somatostatin-secreting delta-cells, we hypothesised that this elevation of alpha-cell output was due to a lack of somatostatin (SST) secretion. Indeed, SST secretion in isolated islets from HFD mice was reduced but exogenous SST also failed to suppress glucagon secretion and [Ca2+]i&nbsp;activity from HFD alpha-cells, in contrast to observations in CTL mice. Conclusions:&nbsp;These findings suggest that reduced delta-cell function, combined with intrinsic changes in alpha-cell sensitivity to somatostatin, accounts for the hyperglucagonaemia in mice fed an HFD.</p

CPT1a-dependent long-chain fatty acid oxidation is essential for maintaining glucagon secretion from pancreatic islets

Glucagon, the principal hyperglycemic hormone, is secreted from pancreatic islet α cells as part of the counter-regulatory response to hypoglycemia. Hence, secretory output from α cells is under high demand in conditions of low glucose supply. Many tissues oxidize fat as an alternate energy substrate. Here, we show that glucagon secretion in low glucose conditions is maintained by fatty acid metabolism in both mouse and human islets, and that inhibiting this metabolic pathway profoundly decreases glucagon output by depolarizing α cell membrane potential and decreasing action potential amplitude. We demonstrate, by using experimental and computational approaches, that this is not mediated by the KATP channel, but instead due to reduced operation of the Na+-K+ pump. These data suggest that counter-regulatory secretion of glucagon is driven by fatty acid metabolism, and that the Na+-K+ pump is an important ATP-dependent regulator of α cell function

Somatostatin secretion by Na+-dependent Ca2+-induced Ca2+ release in pancreatic delta-cells.

Pancreatic islets are complex micro-organs consisting of at least three different cell types: glucagon-secreting α-, insulin-producing β- and somatostatin-releasing δ-cells1. Somatostatin is a powerful paracrine inhibitor of insulin and glucagon secretion2. In diabetes, increased somatostatinergic signalling leads to defective counter-regulatory glucagon secretion3. This increases the risk of severe hypoglycaemia, a dangerous complication of insulin therapy4. The regulation of somatostatin secretion involves both intrinsic and paracrine mechanisms5 but their relative contributions and whether they interact remains unclear. Here we show that dapagliflozin-sensitive glucose- and insulin-dependent sodium uptake stimulates somatostatin secretion by elevating the cytoplasmic Na+ concentration ([Na+]i) and promoting intracellular Ca2+-induced Ca2+ release (CICR). This mechanism also becomes activated when [Na+]i is elevated following the inhibition of the plasmalemmal Na+-K+ pump by reductions of the extracellular K+ concentration emulating those produced by exogenous insulin in vivo6. Islets from some donors with type-2 diabetes hypersecrete somatostatin, leading to suppression of glucagon secretion that can be alleviated by a somatostatin receptor antagonist. Our data highlight the role of Na+ as an intracellular second messenger, illustrate the significance of the intraislet paracrine network and provide a mechanistic framework for pharmacological correction of the hormone secretion defects associated with diabetes that selectively target the δ-cells

Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion.

Hypoglycaemia (low plasma glucose) is a serious and potentially fatal complication of insulin-treated diabetes. In healthy individuals, hypoglycaemia triggers glucagon secretion, which restores normal plasma glucose levels by stimulation of hepatic glucose production. This counterregulatory mechanism is impaired in diabetes. Here we show in mice that therapeutic concentrations of insulin inhibit glucagon secretion by an indirect (paracrine) mechanism mediated by stimulation of intra-islet somatostatin release. Insulin's capacity to inhibit glucagon secretion is lost following genetic ablation of insulin receptors in the somatostatin-secreting δ-cells, when insulin-induced somatostatin secretion is suppressed by dapagliflozin (an inhibitor of sodium-glucose co-tranporter-2; SGLT2) or when the action of secreted somatostatin is prevented by somatostatin receptor (SSTR) antagonists. Administration of these compounds in vivo antagonises insulin's hypoglycaemic effect. We extend these data to isolated human islets. We propose that SSTR or SGLT2 antagonists should be considered as adjuncts to insulin in diabetes therapy

Loss of electrical β-cell to δ-cell coupling underlies impaired hypoglycaemia-induced glucagon secretion in type-1 diabetes

Diabetes mellitus involves both insufficient insulin secretion and dysregulation of glucagon secretion1. In healthy people, a fall in plasma glucose stimulates glucagon release and thereby increases counter-regulatory hepatic glucose production. This response is absent in many patients with type-1 diabetes (T1D)2, which predisposes to severe hypoglycaemia that may be fatal and accounts for up to 10% of the mortality in patients with T1D3. In rats with chemically induced or autoimmune diabetes, counter-regulatory glucagon secretion can be restored by SSTR antagonists4–7 but both the underlying cellular mechanism and whether it can be extended to humans remain unestablished. Here, we show that glucagon secretion is not stimulated by low glucose in isolated human islets from donors with T1D, a defect recapitulated in non-obese diabetic mice with T1D. This occurs because of hypersecretion of somatostatin, leading to aberrant paracrine inhibition of glucagon secretion. Normally, KATP channel-dependent hyperpolarization of β-cells at low glucose extends into the δ-cells through gap junctions, culminating in suppression of action potential firing and inhibition of somatostatin secretion. This ‘electric brake’ is lost following autoimmune destruction of the β-cells, resulting in impaired counter-regulation. This scenario accounts for the clinical observation that residual β-cell function correlates with reduced hypoglycaemia risk8.</p

GLP-1 stimulates insulin secretion by PKC-dependent TRPM4 and TRPM5 activation.

Strategies aimed at mimicking or enhancing the action of the incretin hormone glucagon-like peptide 1 (GLP-1) therapeutically improve glucose-stimulated insulin secretion (GSIS); however, it is not clear whether GLP-1 directly drives insulin secretion in pancreatic islets. Here, we examined the mechanisms by which GLP-1 stimulates insulin secretion in mouse and human islets. We found that GLP-1 enhances GSIS at a half-maximal effective concentration of 0.4 pM. Moreover, we determined that GLP-1 activates PLC, which increases submembrane diacylglycerol and thereby activates PKC, resulting in membrane depolarization and increased action potential firing and subsequent stimulation of insulin secretion. The depolarizing effect of GLP-1 on electrical activity was mimicked by the PKC activator PMA, occurred without activation of PKA, and persisted in the presence of PKA inhibitors, the KATP channel blocker tolbutamide, and the L-type Ca(2+) channel blocker isradipine; however, depolarization was abolished by lowering extracellular Na(+). The PKC-dependent effect of GLP-1 on membrane potential and electrical activity was mediated by activation of Na(+)-permeable TRPM4 and TRPM5 channels by mobilization of intracellular Ca(2+) from thapsigargin-sensitive Ca(2+) stores. Concordantly, GLP-1 effects were negligible in Trpm4 or Trpm5 KO islets. These data provide important insight into the therapeutic action of GLP-1 and suggest that circulating levels of this hormone directly stimulate insulin secretion by β cells.We thank David Wiggins for excellent technical assistance. This work was supported by the Medical Research Council, Diabetes UK (to R. Ramracheya ), Oxford Biomedical Research Centre (to A. Tarasov), the Wellcome Trust (Senior Investigator Awards to A. Galione and P. Rorsman), the Warwick Impact Fund (to C. Weston and G. Ladds), the Biotechnology and Biological Sciences Research Council (to G. Ladds), the Knut and Alice Wallenberg Foundation (to P. Rorsman), and the Swedish Research Council (to P. Rorsman). The initial stages of M. Shigeto’s stay in Oxford were supported by a fellowship from Kawasaki Medical School.This is the final version of the article. It was first available from the American Society for Clinical Investigation via http://dx.doi.org/10.1172/JCI8197

The structural basis of lipid scrambling and inactivation in the endoplasmic reticulum scramblase TMEM16K

Membranes in cells have defined distributions of lipids in each leaflet, controlled by lipid scramblases and flip/floppases. However, for some intracellular membranes such as the endoplasmic reticulum (ER) the scramblases have not been identified. Members of the TMEM16 family have either lipid scramblase or chloride channel activity. Although TMEM16K is widely distributed and associated with the neurological disorder autosomal recessive spinocerebellar ataxia type 10 (SCAR10), its location in cells, function and structure are largely uncharacterised. Here we show that TMEM16K is an ER-resident lipid scramblase with a requirement for short chain lipids and calcium for robust activity. Crystal structures of TMEM16K show a scramblase fold, with an open lipid transporting groove. Additional cryo-EM structures reveal extensive conformational changes from the cytoplasmic to the ER side of the membrane, giving a state with a closed lipid permeation pathway. Molecular dynamics simulations showed that the open-groove conformation is necessary for scramblase activity

Developing optogenetics for use in vascular research

Optogenetics is a recently established experimental technique that involves the heterologous expression of light sensitive proteins (opsins) in mammalian cells to modulate cell function. One of the most commonly used opsin is the blue light gated depolarising channel, channelrhodopsin-2 (ChR2). Optogenetics involving ChR2 has revolutionised the field of neuroscience by enabling the definition of novel brain circuitries. Optogenetic control of the electromechanical coupling in vascular smooth muscle cells (SMCs) is now emerging as a powerful research tool with potential applications in drug discovery and therapeutics. However, the exact ionic mechanisms involved in this control remain unclear. The overall aim of this thesis was to establish ChR2 for use in vascular optogenetics. The main findings of this thesis are: 1) Blue light activation of ChR2 and the ChR2 variant ChR2(H134R) led to long-lasting and non-inactivating depolarising currents. 2) Transgenic mice expressing ChR2(H134R) selectively in SMCs were generated. Isolated SMCs obtained from these mice demonstrated blue light induced depolarising whole-cell currents. Fine control of artery tone was attained by varying the intensity of the blue light stimulus. This arterial response was sufficient to overcome the melanopsin-mediated light-depended arterial relaxation observed in the presence of contraction-eliciting agonists. 3) Pharmacological analyses revealed that Ca2+ entry through voltage-gated Ca2+ channels, and recruitment of plasmalemmal depolarising channels (TMEM16A and TRPM) and intracellular IP3 receptors were mandatory for the ChR2(H134R)-mediated arterial response to blue light at intensities &amp;LT;~0.1 mW/mm2. Light stimuli of greater power evoked a significant Ca2+ influx directly through ChR2(H134R) and produced dramatic intracellular alkalinisation of the SMCs. The light intensity range that enables optical control of arterial tone primarily through the recruitment of endogenous channels and without substantial alteration of intracellular pH, was identified. Within this range, mice expressing ChR2(H134R) in SMCs are a powerful experimental model for achieving accurate and tuneable optical voltage-clamp of SMCs and finely-graded control of arterial tone, offering new avenues to the discovery of vasorelaxing drugs. 4) The Cl--selective ChR2 mutant iChloC mediates depolarising currents while also preventing H+ or Ca2+ fluxes. This mutant was also found to have enhanced sensitivity to blue light. This new optogenetic tool could be a good candidate for an improved mouse model of vascular optogenetics. To conclude, the work presented in this thesis represents an in depth analysis of the use of ChR2(H134R) in vascular optogenetics. The cellular mechanism linking ChR2(H134R) opening with contraction of vascular SMCs was defined. Additionally, the limitations of the current optogenetic mouse model have been identified, and iChloC was shown to resolve these limitations. This study established vascular optogenetics as novel research tool vascular physiology and pharmacology.</p